Cargando…

Reduced occipital GABA in Parkinson disease with visual hallucinations

OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and...

Descripción completa

Detalles Bibliográficos
Autores principales: Firbank, Michael J., Parikh, Jehill, Murphy, Nicholas, Killen, Alison, Allan, Charlotte L., Collerton, Daniel, Blamire, Andrew M., Taylor, John-Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105043/
https://www.ncbi.nlm.nih.gov/pubmed/30021920
http://dx.doi.org/10.1212/WNL.0000000000006007
_version_ 1783349596604334080
author Firbank, Michael J.
Parikh, Jehill
Murphy, Nicholas
Killen, Alison
Allan, Charlotte L.
Collerton, Daniel
Blamire, Andrew M.
Taylor, John-Paul
author_facet Firbank, Michael J.
Parikh, Jehill
Murphy, Nicholas
Killen, Alison
Allan, Charlotte L.
Collerton, Daniel
Blamire, Andrew M.
Taylor, John-Paul
author_sort Firbank, Michael J.
collection PubMed
description OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and 17 without complex visual hallucinations, together with 20 healthy controls without hallucinations. In addition, we acquired T1-weighted MRI, whole-brain fMRI during a visual task, and diffusion tensor imaging. RESULTS: We found lower GABA+/creatine in PD with visual hallucinations (0.091 ± 0.010) vs those without (0.101 ± 0.010) and controls (0.099 ± 0.010) (F(2,49) = 4.5; p = 0.016). Reduced gray matter in the hallucinations group was also observed in the anterior temporal lobe. Although there were widespread reductions in white matter integrity in the visual hallucinations group, this was no longer significant after controlling for cognitive function. CONCLUSIONS: The data suggest that reduced levels of GABA are associated with visual hallucinations in PD and implicate changes to the ventral visual stream in the genesis of visual hallucinations. Modulation of visual cortical excitability through, for example, pharmacologic intervention, may be a promising treatment avenue to explore.
format Online
Article
Text
id pubmed-6105043
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61050432018-08-23 Reduced occipital GABA in Parkinson disease with visual hallucinations Firbank, Michael J. Parikh, Jehill Murphy, Nicholas Killen, Alison Allan, Charlotte L. Collerton, Daniel Blamire, Andrew M. Taylor, John-Paul Neurology Article OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and 17 without complex visual hallucinations, together with 20 healthy controls without hallucinations. In addition, we acquired T1-weighted MRI, whole-brain fMRI during a visual task, and diffusion tensor imaging. RESULTS: We found lower GABA+/creatine in PD with visual hallucinations (0.091 ± 0.010) vs those without (0.101 ± 0.010) and controls (0.099 ± 0.010) (F(2,49) = 4.5; p = 0.016). Reduced gray matter in the hallucinations group was also observed in the anterior temporal lobe. Although there were widespread reductions in white matter integrity in the visual hallucinations group, this was no longer significant after controlling for cognitive function. CONCLUSIONS: The data suggest that reduced levels of GABA are associated with visual hallucinations in PD and implicate changes to the ventral visual stream in the genesis of visual hallucinations. Modulation of visual cortical excitability through, for example, pharmacologic intervention, may be a promising treatment avenue to explore. Lippincott Williams & Wilkins 2018-08-14 /pmc/articles/PMC6105043/ /pubmed/30021920 http://dx.doi.org/10.1212/WNL.0000000000006007 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Firbank, Michael J.
Parikh, Jehill
Murphy, Nicholas
Killen, Alison
Allan, Charlotte L.
Collerton, Daniel
Blamire, Andrew M.
Taylor, John-Paul
Reduced occipital GABA in Parkinson disease with visual hallucinations
title Reduced occipital GABA in Parkinson disease with visual hallucinations
title_full Reduced occipital GABA in Parkinson disease with visual hallucinations
title_fullStr Reduced occipital GABA in Parkinson disease with visual hallucinations
title_full_unstemmed Reduced occipital GABA in Parkinson disease with visual hallucinations
title_short Reduced occipital GABA in Parkinson disease with visual hallucinations
title_sort reduced occipital gaba in parkinson disease with visual hallucinations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105043/
https://www.ncbi.nlm.nih.gov/pubmed/30021920
http://dx.doi.org/10.1212/WNL.0000000000006007
work_keys_str_mv AT firbankmichaelj reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT parikhjehill reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT murphynicholas reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT killenalison reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT allancharlottel reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT collertondaniel reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT blamireandrewm reducedoccipitalgabainparkinsondiseasewithvisualhallucinations
AT taylorjohnpaul reducedoccipitalgabainparkinsondiseasewithvisualhallucinations